Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3502970 in Participants With Normal Renal Function and Renal Impairment
NCT05936138Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of orforglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity, Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point and 1 more. Started Jul 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05936138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936138.